Collection of Sputum and Labeling for Lung Cancer



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:21 - Any
Updated:10/20/2018
Start Date:March 1, 2018
End Date:April 2019
Contact:Maria Zannes, JD
Email:mz@bioaffinitytech.com
Phone:505-400-9747

Use our guide to learn which trials are right for you!

Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer

The primary objective of this study is to compare Assay results to diagnoses determined by
currently accepted standards for lung cancer detection. This will be accomplished by analysis
of sputum samples from three cohorts including healthy Participants, high risk Participants,
and cancer patient Participants using the Assay as developed in accordance with findings of
bioAffinity protocol BA-001 to confirm assay results. Adjustments will be made as necessary
to finalize Assay design for clinical trials and commercialization.

The secondary objective of this study is to determine optimum methods for collection of
sputum samples. Three sputum collection methods used by high risk Participants will be
compared. Individuals at high risk for lung cancer will be assigned to one of three sputum
collection cohorts including (1) acapella® airway assist device under medical supervision to
obtain a single sputum sample; (2) acapella® airway assist device to obtain a sputum sample
over a three-day period, and (3) individuals who under medical supervision will collect a
single sputum sample assisted by nebulization of between 0.9% to 10% hypertonic saline.
Samples will be compared to determine the optimal collection method for sample analysis by
CyPath® Lung.

This study will be performed at multiple study centers to collect sputum samples from three
cohorts including (1) healthy Participants, (2) individuals at high risk for lung cancer and
(3) individuals who have been diagnosed with lung cancer. Participants in the high risk
cohort will undergo low dose computed tomography (LDCT) scans to confirm they do not have
lung cancer. LDCT scans will be evaluated by a radiologist at each site. Each subject's
sputum specimen will be processed in accordance with individual experimental protocol at the
laboratory of bioAffinity Technologies, Inc. (BA) located at the University of Texas at San
Antonio 1604 main campus in San Antonio, Texas, or at the Research DX laboratory in Irvine,
California.

Once a sample is obtained and delivered to the laboratory, the Assay methodology consists of
chemical dissociation of sputum to produce a single cell suspension sample that is labeled
with antibodies to identify various types of cell populations in the sample. Thereafter,
sputum samples are stained with the cancer detection compound, CyPath® Lung. This compound
has a unique fluorescent spectrum that can be analyzed by a flow cytometer. The flow
cytometric analysis confirms that the sample is from the deep lung and identifies various
cell populations based on characteristics such as cell size, granularity, and antigen
expression. Cancer samples can be distinguished from non-cancer samples by the presence of
highly fluorescent cells labeled by CyPath®. In this manner, CyPath® can identify lung cancer
cells and other distinguishing cells that have been sloughed off in the lungs and coughed up
in the sputum sample, including cancer cells.

Researchers who will be blinded as to the Participant's identity will perform the experiments
that compare the characteristics of samples collected by the alternate sample collection
methods and labeled by CyPath® Lung. In the latter phase of the study, the analytical results
of sputum sample analysis requires that the researchers be blinded to the classification of
the sputum sample and methods of collection.

Findings from the CyPath® Lung Assay will not be used in the diagnosis of Participants or
subsequent treatment decisions.

Inclusion Criteria:

Each subject must meet the following criteria to be enrolled in this study:

- Male or female

- 21 years of age or older

- Willing to provide primary care physician contact information to the investigator and
agree to have medical information released if indicated

- Meet requirements of one of three cohorts in the study:

Healthy Cohort: Current non-smoker who has smoked less than 5 pack-years in his or her
lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease.

High Risk Cohort: Individual aged ≥55-74 who is a current smoker with a smoking history of
at least 30 pack-years, or current non-smoker who has a smoking history of at least 30
pack-years, and quit smoking within the past 15 years.

Cancer Cohort: Individual who has been diagnosed by a physician as highly suspect for
having lung cancer but has not yet undergone a biopsy nor received therapy, and after
providing a sputum sample is confirmed to have lung cancer by biopsy.

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from the study:

- Severe obstructive lung disease and unable to cough with sufficient exertion to
produce a sputum sample. Participants with lung disease that are able to cough with
sufficient exertion to produce a sputum sample are not excluded from the study

- Angina with minimal exertion

- Pregnancy
We found this trial at
7
sites
1 Medical Center Boulevard
Cookeville, Tennessee 61801
Principal Investigator: Paul Jacquin, MD
Phone: 931-783-2256
?
mi
from
Cookeville, TN
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Kathleen Lopez, MD
Phone: 505-506-0853
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Berkeley Heights, New Jersey 07922
Principal Investigator: Sarada Gurubhagavatula, MD
Phone: 908-721-5673
?
mi
from
Berkeley Heights, NJ
Click here to add this to my saved trials
New York, New York 10029
Principal Investigator: Louis R DePalo, MD
Phone: 212-241-9538
?
mi
from
New York, NY
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Sheila Habib, MD
Phone: 210-834-1344
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
99 Beauvoir Avenue
Summit, New Jersey 07901
Principal Investigator: Robert Sussman, MD
Phone: 908-934-0440
?
mi
from
Summit, NJ
Click here to add this to my saved trials
Waterbury, Connecticut
Principal Investigator: David G. Hill, MD
Phone: 203-759-3656
?
mi
from
Waterbury, CT
Click here to add this to my saved trials